The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containing such molecules, and processes of using such molecules against such pests. These molecules may be used, for example, as nematicides, acaricides, insecticides, miticides, and/or molluscicides. This document discloses molecules having the following formula (“Formula One”).

##STR00001##

Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

A crystalline form of CXCR2 antagonist, such as Compound 1, is used in preparing a drug for treating CXCR2-related diseases.

##STR00001##

The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Provided are: a nucleating agent for a polyolefin resin having an excellent β crystal-forming effect; a nucleating agent composition for a polyolefin resin containing the nucleating agent; a polyolefin resin masterbatch; a polyolefin resin composition; a molded article of the composition; a film of the composition; a method of producing a porous film; and a package. The nucleating agent contains a compound represented by Formula (1) below wherein M represents a monovalent to trivalent metal atom having a specific gravity of 4.0 or less, or the like; a represents 1 or 2; b represents 1 or 3; x represents an integer of 1 to 3; ax=2b is satisfied; and Z represents a group represented by Formula (2) or (3) below wherein * represents a position at which each group is linked with Z of Formula (1); Y represents a direct bond or an alkylene group having 1 to 4 carbon atoms; and R.sub.1 to R.sub.10 each independently represent a hydrogen atom, a hydroxy group, a halogen atom, an alkyl group having 1 to 10 carbon atoms, or the like.

##STR00001##

Provided are: a nucleating agent for a polyolefin resin having an excellent β crystal-forming effect; a nucleating agent composition for a polyolefin resin containing the nucleating agent; a polyolefin resin masterbatch; a polyolefin resin composition; a molded article of the composition; a film of the composition; a method of producing a porous film; and a package. The nucleating agent contains a compound represented by Formula (1) below wherein M represents a monovalent to trivalent metal atom having a specific gravity of 4.0 or less, or the like; a represents 1 or 2; b represents 1 or 3; x represents an integer of 1 to 3; ax=2b is satisfied; and Z represents a group represented by Formula (2) or (3) below wherein * represents a position at which each group is linked with Z of Formula (1); Y represents a direct bond or an alkylene group having 1 to 4 carbon atoms; and R.sub.1 to R.sub.10 each independently represent a hydrogen atom, a hydroxy group, a halogen atom, an alkyl group having 1 to 10 carbon atoms, or the like.

##STR00001##